Barclays Issues Pessimistic Forecast for Sangamo Therapeutics (NASDAQ:SGMO) Stock Price

Sangamo Therapeutics (NASDAQ:SGMO) had its target price lowered by equities researchers at Barclays from $9.00 to $5.00 in a report issued on Wednesday,Benzinga reports. The firm presently has an “overweight” rating on the biopharmaceutical company’s stock.

Several other brokerages have also recently commented on SGMO. Truist Financial decreased their target price on shares of Sangamo Therapeutics from $7.00 to $5.00 and set a “buy” rating for the company in a research report on Thursday, January 23rd. HC Wainwright reiterated a “buy” rating and set a $10.00 price objective on shares of Sangamo Therapeutics in a research report on Monday, April 7th. Finally, Royal Bank of Canada reissued a “sector perform” rating and set a $2.00 target price on shares of Sangamo Therapeutics in a research note on Tuesday, March 18th. Three investment analysts have rated the stock with a hold rating and four have given a buy rating to the stock. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus price target of $4.50.

Sangamo Therapeutics Stock Up 2.7%

SGMO stock opened at $0.45 on Wednesday. The company’s 50-day moving average price is $0.74 and its two-hundred day moving average price is $1.33. The firm has a market cap of $103.14 million, a P/E ratio of -0.60 and a beta of 1.46. Sangamo Therapeutics has a 12 month low of $0.30 and a 12 month high of $3.18.

Sangamo Therapeutics (NASDAQ:SGMO) last released its quarterly earnings data on Monday, May 12th. The biopharmaceutical company reported ($0.14) earnings per share for the quarter, missing the consensus estimate of ($0.11) by ($0.03). Sangamo Therapeutics had a negative net margin of 257.87% and a negative return on equity of 264.16%. The business had revenue of $6.44 million during the quarter, compared to analyst estimates of $7.90 million. Equities analysts predict that Sangamo Therapeutics will post -0.46 EPS for the current year.

Institutional Inflows and Outflows

Institutional investors have recently made changes to their positions in the company. E Fund Management Co. Ltd. purchased a new position in Sangamo Therapeutics in the 4th quarter worth approximately $25,000. JPMorgan Chase & Co. grew its position in Sangamo Therapeutics by 679.5% in the fourth quarter. JPMorgan Chase & Co. now owns 25,000 shares of the biopharmaceutical company’s stock worth $26,000 after acquiring an additional 21,793 shares in the last quarter. PNC Financial Services Group Inc. increased its stake in Sangamo Therapeutics by 2,319.1% in the fourth quarter. PNC Financial Services Group Inc. now owns 26,078 shares of the biopharmaceutical company’s stock valued at $27,000 after acquiring an additional 25,000 shares during the last quarter. SBI Securities Co. Ltd. purchased a new stake in Sangamo Therapeutics during the fourth quarter valued at about $28,000. Finally, Shelton Wealth Management LLC purchased a new stake in Sangamo Therapeutics during the fourth quarter valued at about $29,000. Institutional investors own 56.93% of the company’s stock.

About Sangamo Therapeutics

Sangamo Therapeutics, Inc, a clinical-stage genomic medicine company, focuses on translating science into medicines that transform the lives of patients and families afflicted with serious diseases in the United States. The company's clinical-stage product candidates are ST-920, a gene therapy product candidate, which is in Phase 1/2 clinical study for the treatment of Fabry disease; TX200, a chimeric antigen receptor engineered regulatory T cell (CAR-Treg) therapy product candidate that is in Phase 1/2 clinical study for the prevention of immune-mediated rejection in HLA-A2 mismatched kidney transplantation; SB-525, a gene therapy product candidate, which is in Phase 3 clinical trial for the treatment of moderately severe to severe hemophilia A; BIVV003, a zinc finger nuclease gene-edited cell therapy product candidate that is in Phase 1/2 PRECIZN-1 clinical study for the treatment of sickle cell disease.